APA
Vergnenègre A., Basse V., Le Garff G., Bylicki O., Dubos-Arvis C., Comet B., Marcq M., Le Treut J., Auliac J., Madroszyk A., Fraboulet G., Crequit J., Thomas P., Paleiron N. & Monnet I. (2019). Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). : Cancer management and research.
Chicago
Vergnenègre Alain, Basse Victor, Le Garff Gwenaelle, Bylicki Olivier, Dubos-Arvis Catherine, Comet Bénédicte, Marcq Marie, Le Treut Jacques, Auliac Jean-Bernard, Madroszyk Anne, Fraboulet Gislaine, Crequit Jacky, Thomas Pascal, Paleiron Nicolas and Monnet Isabelle. 2019. Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). : Cancer management and research.
Harvard
Vergnenègre A., Basse V., Le Garff G., Bylicki O., Dubos-Arvis C., Comet B., Marcq M., Le Treut J., Auliac J., Madroszyk A., Fraboulet G., Crequit J., Thomas P., Paleiron N. and Monnet I. (2019). Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). : Cancer management and research.
MLA
Vergnenègre Alain, Basse Victor, Le Garff Gwenaelle, Bylicki Olivier, Dubos-Arvis Catherine, Comet Bénédicte, Marcq Marie, Le Treut Jacques, Auliac Jean-Bernard, Madroszyk Anne, Fraboulet Gislaine, Crequit Jacky, Thomas Pascal, Paleiron Nicolas and Monnet Isabelle. Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). : Cancer management and research. 2019.